Next Article in Journal
Targeting NF-κB-Inducing Kinase (NIK) in Immunity, Inflammation, and Cancer
Next Article in Special Issue
Molecular Mechanisms of Treatment Resistance in Glioblastoma
Previous Article in Journal
Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis
Previous Article in Special Issue
MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Mechanisms of EGFR Resistance in Glioblastoma

1
Division of Neuro-Oncology, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY 10032, USA
2
Division of Neuro-Oncology, NewYork-Presbyterian/Weill Cornell Medicine, New York, NY 10021, USA
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(22), 8471; https://doi.org/10.3390/ijms21228471
Submission received: 10 September 2020 / Revised: 4 November 2020 / Accepted: 9 November 2020 / Published: 11 November 2020
(This article belongs to the Special Issue Molecular and Cellular Hallmarks of Malignant Brain Tumors)

Abstract

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Despite numerous efforts to target epidermal growth factor receptor (EGFR), commonly dysregulated in GBM, approaches directed against EGFR have not achieved the same degree of success as seen in other tumor types, particularly as compared to non-small cell lung cancer (NSCLC). EGFR alterations in glioblastoma lie primarily in the extracellular domain, unlike the kinase domain alterations seen in NSCLC. Small molecule inhibitors are difficult to develop for the extracellular domain. Monoclonal antibodies can be developed to target the extracellular domain but must contend with the blood brain barrier (BBB). We review the role of EGFR in GBM, the history of trialed treatments, and the potential paths forward to target the pathway that may have greater success.
Keywords: epidermal growth factor receptor; treatment resistance; heterogeneity; glioblastoma epidermal growth factor receptor; treatment resistance; heterogeneity; glioblastoma

Share and Cite

MDPI and ACS Style

Pan, P.C.; Magge, R.S. Mechanisms of EGFR Resistance in Glioblastoma. Int. J. Mol. Sci. 2020, 21, 8471. https://doi.org/10.3390/ijms21228471

AMA Style

Pan PC, Magge RS. Mechanisms of EGFR Resistance in Glioblastoma. International Journal of Molecular Sciences. 2020; 21(22):8471. https://doi.org/10.3390/ijms21228471

Chicago/Turabian Style

Pan, Peter C., and Rajiv S. Magge. 2020. "Mechanisms of EGFR Resistance in Glioblastoma" International Journal of Molecular Sciences 21, no. 22: 8471. https://doi.org/10.3390/ijms21228471

APA Style

Pan, P. C., & Magge, R. S. (2020). Mechanisms of EGFR Resistance in Glioblastoma. International Journal of Molecular Sciences, 21(22), 8471. https://doi.org/10.3390/ijms21228471

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop